Cassiopea SpA. Cassiopea SpA is an Italy-based company engaged in the biotechnology and medical research industry. The Company is a clinical stage specialty pharmaceutical company focused on developing and commercializing innovative and differentiated medical dermatology products. The Company's current focus is on the topical treatment of acne, androgenic alopecia (''AGA'') and genital warts. Its portfolio comprises four clinical candidates, such as Winlevi, Breezula, CB-06-01 and CB-06-02, for which the Company owns the worldwide rights. These product candidates are based on three chemical entities (''NCE''). They target unmet medical needs and addressable opportunities in the medical dermatology market. The main shareholder of the Company is Cosmo Pharmaceuticals SA.
theScreener is the market leader for independent valuations of financial securities, equities, sectors and markets, and new funds. theScreener's ratings, analyses are used by leading banks, asset managers and financial portals. Approximately 10,000 workstations benefit from theScreener's services, with over millions of customer accounts actively analysed.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.